-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately

Benzinga·02/09/2026 13:08:52
Listen to the news

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately.

Dr. Rochlin has served as IN8bio's Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.